Cocrystal Pharma, Inc. — Director's Dealing 2018

Sep 24, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2018-09-21

Reporting Person: WILCOX GARY (Director, Interim CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-21	Stock Options (Right to Buy)	$2.78	A	200000	Acquired	2028-09-20	Common Stock (200000)	Direct

Footnotes

F1: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments.

F2: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year.